Leap Therapeutics Inc.

NASDAQ: LPTX · Real-Time Price · USD
0.42
0.03 (6.87%)
At close: Jun 09, 2025, 3:59 PM

Leap Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 634K 634K 634K 634K n/a n/a n/a n/a 375K 750K 1.13M 1.5M 1.5M 1.5M 1.5M
Cost of Revenue
n/a 5K 115K 222K 328K 427K 418K 411K 411K 415K 688.63K 588.63K 482.63K 374.63K n/a n/a n/a
Gross Profit
n/a -5K 519K 412K 306K 207K -418K -411K -411K -415K -313.63K 161.38K 642.38K 1.13M 1.5M 1.5M 1.5M
Operating Income
-71.15M -70.06M -68.75M -65.73M -59.14M -87.04M -86.16M -86.62M -88.86M -56.76M -53.31M -50.16M -42.89M -41.43M -38.09M -33.46M -31.33M
Interest Income
2.79M 3.13M 3.47M 3.66M 3.95M 4.03M 3.61M 2.89M 1.77M 925K 409K 50K 12K 9K 9K 11K 30K
Pretax Income
-68.58M -66.97M -63.88M -60.11M -53.37M -81.41M -80.9M -82.3M -85.94M -54.45M -53.31M -49.35M -41.85M -40.61M -36.51M -32.43M -29.42M
Net Income
-69.17M -67.56M -64.59M -60.11M -53.37M -80.55M -80.19M -82.39M -86.76M -55.9M -54.59M -49.83M -41.59M -40.59M -36.51M -32.43M -29.42M
Selling & General & Admin
12.33M 12.85M 12.86M 13.25M 13.44M 13.7M 13.58M 13.44M 12.73M 11.8M 11.68M 10.93M 10.87M 10.77M 10.4M 10.48M 10.2M
Research & Development
58.82M 57.21M 55.78M 52.37M 45.59M 73.23M 72.58M 73.18M 76.12M 44.97M 42M 39.98M 33.14M 32.16M 29.19M 24.48M 22.63M
Other Expenses
n/a n/a 272K 272K 272K n/a -1.05M -1.7M -2.29M -2.05M 308K -309K 34K n/a -1.58M -315K -71K
Operating Expenses
71.15M 70.06M 68.64M 65.62M 58.73M 86.36M 84.82M 84.62M 86.57M 54.71M 52.77M 49.38M 42.82M 41.7M 38.12M 34.53M 32.61M
Interest Expense
-6K n/a 863K 863K 863K 863K 5K 16K 33K 54K 51K 49K 48K 41K 39K 47K 44K
Selling & Marketing Expenses
n/a n/a -110K -110K -110K -110K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
55.24M 70.06M 68.75M 65.73M 58.84M 86.47M 84.82M 84.62M 86.57M 54.71M 52.77M 49.38M 42.82M 41.7M 38.12M 34.53M 32.61M
Income Tax Expense
585K 580K 1.37M 858K 841.91K -16.09K -533.09K 74.92K 824K 1.45M 1.28M 483K -146K 1K 23K 31K -60K
Shares Outstanding (Basic)
41.27M 41.25M 41.21M 39.12M 27.01M 26.99M 26.99M 14.71M 12.93M 11.32M 11.32M 11.32M 11.32M 11.31M 7.82M 7.64M 7.64M
Shares Outstanding (Diluted)
41.27M 41.25M 41.21M 39.12M 27.01M 26.99M 26.99M 14.71M 12.93M 11.32M 11.32M 11.32M 11.32M 11.31M 7.82M 7.64M 7.64M
EPS (Basic)
-1.69 -1.83 -1.92 -1.99 -2.39 -5.05 -5.66 -6.55 -7.21 -4.94 -4.82 -4.84 -4.52 -4.82 -4.75 -4.25 -4.24
EPS (Diluted)
-1.69 -1.83 -1.92 -1.99 -2.39 -5.05 -5.66 -6.55 -7.21 -4.94 -4.82 -4.84 -4.52 -4.82 -4.75 -4.25 -4.24
EBITDA
-71.65M -70.56M -67.26M -62.49M -54.53M -81.46M -80.48M -81.88M -85.49M -53.98M -52.72M -48.8M -41.28M -40.14M -36.13M -31.97M -28.93M
EBIT
-54.91M -69.49M -66.4M -61.74M -55.1M -82.98M -82.46M -83.85M -86.49M -54.4M -53.26M -49.3M -41.8M -40.57M -36.48M -32.38M -29.38M
Depreciation & Amortization
-297K -292K -182K 424K 328K 427K 418K 411K 411K 415K 531K 497K 528K 556K -59K -26K -31K